KCNK2
MOLECULAR TARGETpotassium two pore domain channel subfamily K member 2
KCNK2 (potassium two pore domain channel subfamily K member 2) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KCNK2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | propafenone | 4.53 | 92 |
| 2 | pimozide | 4.19 | 65 |
| 3 | flufenamic acid | 4.14 | 62 |
| 4 | fluphenazine | 3.91 | 49 |
| 5 | flupentixol | 2.56 | 12 |
| 6 | norfluoxetine | 1.95 | 6 |
| 7 | Amlodipine | 1.10 | 2 |
| 8 | Arachidonic Acid | 0.69 | 1 |
| 9 | Carvedilol | 0.69 | 1 |
| 10 | Flunarizine Flunarizine is | 0.69 | 1 |
| 11 | Fluspirilene | 0.69 | 1 |
| 12 | Riluzole | 0.69 | 1 |
About KCNK2 as a Drug Target
KCNK2 (potassium two pore domain channel subfamily K member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented KCNK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KCNK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.